

Catalog# BP-50541

Nimotuzumab Biosimilar, EGFR Monoclonal Antibody

Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.

Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signaling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.

It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ -chain.

Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Product Details	
CAS No.	780758-10-3
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Nimotuzumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human epidermal growth factor receptor (EGFR)
Purity	>95%
Molecular Weight	147.58 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 μ M filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.